The promise of pemigatinib for patients with FGFR1-rearranged MLN

FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangementПодробнее

FDA approval of pemigatinib for R/R myeloid/lymphoid neoplasms: a major advance in the fieldПодробнее

Insights into pemigatinib and the recent FDA approval of this agentПодробнее

Top MPNs news at ASH 2021: pemigatinib, rusfertide, avapritinib and pelabresibПодробнее

The promise of pelabresib in MF and insights into the MANIFEST-2 studyПодробнее

Revolutionary Treatment Developments for Myeloid/ Lymphoid Neoplasms (MLN) | Dr. Serge VertovsekПодробнее

Recent advances in eosinophilia with FGFR rearrangementПодробнее

The impact of the FDA approval of pemigatinibПодробнее

Inflammasomes - Cellular Immunology Case StudyПодробнее

Transfusion Medicine: Problems and Solutions, Brief SummaryПодробнее

Analysis of long-term exposure to momelotinib in the Phase III SIMPLFY myelofibrosis trialsПодробнее

Hematopathology-Lymphoid-Richter's_CLL.mp4Подробнее

Consistency of pacritinib in patients with MF: pooled analysis from PERSIST-1 & PERSIST-2Подробнее

The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202Подробнее

FIGHT-202: pemigatinib in CCAПодробнее

PriotheraПодробнее

FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinomaПодробнее

Pembrolizumab demonstrates promise in patients with pretreated metastatic gastric cancerПодробнее

FDA Approved Pemigatinib new drug for cholangiocarcinoma, $18, 448 For 14 Days, But I'm 2 Die 2Подробнее